Ventana ALK regulatory update

FDA approved the Ventana ALK (D5F3) CDx Assay from Roche’s Ventana Medical Systems Inc. unit for the qualitative detection of anaplastic lymphoma kinase (ALK) protein in non-small cell lung cancer (NSCLC) sample and as an aid in identifying patients eligible for treatment with Pfizer’s Xalkori crizotinib. The automated immunohistochemistry (IHC) test runs on the Ventana BenchMark IHC instruments. The test is approved in Europe and China. ...